{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:09:16Z","timestamp":1780092556476,"version":"3.54.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Remimazolam is not only associated with a lower incidence of respiratory depression than propofol but also in itself has the risk of respiratory depression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>We investigated respiratory depression following remimazolam infusion, targeting different effect-site concentrations using target-controlled infusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN<\/jats:title>\n            <jats:p>A prospective, double-blind, randomised controlled study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING<\/jats:title>\n            <jats:p>Tertiary hospital, Suwon, South Korea, from April 2022 to November 2022.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PARTICIPANTS<\/jats:title>\n            <jats:p>One hundred and seven patients scheduled for general anaesthesia were randomised into three groups targeting remimazolam effect-site concentrations of 500 (RMZ-500) (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a36), 1000 (RMZ-1000) (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a35) and 1500\u200ang\u200aml<jats:sup>\u22121<\/jats:sup> (RMZ-1500) (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a36).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTIONS<\/jats:title>\n            <jats:p>Remimazolam was solely infused for 10\u200amin according to target effect-site concentrations. According to the degree of SpO<jats:sub>2<\/jats:sub> decrease, oxygen desaturations were managed with the following respiratory supports: jaw-thrust for SpO<jats:sub>2<\/jats:sub> less than 97%, 100% oxygen delivery for SpO<jats:sub>2<\/jats:sub> less than 93% and assisted ventilation for SpO<jats:sub>2<\/jats:sub> less than 90%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOME MEASURES<\/jats:title>\n            <jats:p>The incidence of each respiratory support, along with respiratory variables (at baseline, 5\u200amin and 10\u200amin after remimazolam infusion) and loss of consciousness were observed for 10\u200amin after remimazolam target-controlled infusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Both RMZ-1000 and RMZ-1500 required more frequent respiratory support than RMZ-500 (both <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001), with nearly identical frequencies between RMZ-1000 and RMZ-1500. In terms of respiratory support, the incidence of assisted ventilation was significantly lower in RMZ-500 (2.8%) than RMZ-1000 (48.6%) and RMZ-1500 (50%) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001). RMZ-1000 and RMZ-1500 achieved loss of consciousness in all patients; RMZ-500 only achieved loss of consciousness in 86.1% of patients (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.010). In patients who maintained spontaneous respiration, tidal volume decreased by 41 to 48% and respiratory rate increased by 118 to 158% at 5 and 10\u200amin, significantly compared to baseline in all groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS<\/jats:title>\n            <jats:p>Remimazolam infusion, like that of other benzodiazepines, led to respiratory depression, which was more prominent at higher target effect-site concentrations. Therefore, appropriate countermeasures should be developed to prevent oxygen desaturation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>TRIAL REGISTRATION<\/jats:title>\n            <jats:p>CRIS (https:\/\/cris.nih.go.kr), identifier: KCT0006952<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/eja.0000000000002045","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:00:43Z","timestamp":1722312043000},"page":"728-737","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["The degree of respiratory depression according to the effect-site concentration in remimazolam target-controlled infusion"],"prefix":"10.1097","volume":"41","author":[{"given":"Soo Jung","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kee","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyubin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"R1-20250801","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2334\/josnusd.21-0051","article-title":"Sedation outcomes for remimazolam, a new benzodiazepine","volume":"63","author":"Oka","year":"2021","journal-title":"J Oral Sci"},{"key":"R2-20250801","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/jgh.15188","article-title":"Remimazolam tosilate in upper gastrointestinal endoscopy: a multicenter, randomized, noninferiority, phase III trial","volume":"36","author":"Chen","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R3-20250801","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4097\/kjae.2011.61.2.122","article-title":"The effect-site concentration of propofol producing respiratory depression during spinal anesthesia","volume":"61","author":"Lee","year":"2011","journal-title":"Korean J Anesthesiol"},{"key":"R4-20250801","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.2174\/1381612043382846","article-title":"Propofol: therapeutic indications and side-effects","volume":"10","author":"Marik","year":"2004","journal-title":"Curr Pharm Des"},{"key":"R5-20250801","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/ACO.0000000000000877","article-title":"Remimazolam for anaesthesia or sedation","volume":"33","author":"Sneyd","year":"2020","journal-title":"Curr Opin Anaesthesiol"},{"key":"R6-20250801","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4266\/acc.2022.00619","article-title":"Review of remimazolam and sedatives in the intensive care unit","volume":"37","author":"Choi","year":"2022","journal-title":"Acute Crit Care"},{"key":"R7-20250801","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1399-6576.1987.tb02643.x","article-title":"Changes in respiratory pattern after repeated doses of diazepam and midazolam in healthy subjects","volume":"31","author":"Berggren","year":"1987","journal-title":"Acta Anaesthesiol Scand"},{"key":"R8-20250801","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1055\/s-0033-1344645","article-title":"Target-controlled infusion vs. manually controlled infusion of propofol with alfentanil for bidirectional endoscopy: a randomized controlled trial","volume":"45","author":"Chiang","year":"2013","journal-title":"Endoscopy"},{"key":"R9-20250801","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1213\/ANE.0000000000000685","article-title":"Target-controlled infusions could improve the safety and efficacy of emergency department propofol sedation","volume":"122","author":"Green","year":"2016","journal-title":"Anesth Analg"},{"key":"R10-20250801","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1213\/ane.0b013e318198f6dc","article-title":"Manual versus target-controlled infusion remifentanil administration in spontaneously breathing patients","volume":"108","author":"Moerman","year":"2009","journal-title":"Anesth Analg"},{"key":"R11-20250801","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17085\/apm.21115","article-title":"Remimazolam: pharmacological characteristics and clinical applications in anesthesiology","volume":"17","author":"Kim","year":"2022","journal-title":"Anesth Pain Med (Seoul)"},{"key":"R12-20250801","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/ALN.0000000000003103","article-title":"Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: Part I. Pharmacokinetics and clinical pharmacodynamics","volume":"132","author":"Sch\u00fcttler","year":"2020","journal-title":"Anesthesiology"},{"key":"R13-20250801","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1213\/ANE.0000000000006718","article-title":"Comparative analysis of the performance of electroencephalogram parameters for monitoring the depth of sedation during remimazolam target-controlled infusion","volume":"138","author":"Bae","year":"2023","journal-title":"Anesth Analg"},{"key":"R14-20250801","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/ALN.0000000000004811","article-title":"Target controlled infusion of remimazolam in healthy volunteers shows some acute tolerance","volume":"140","author":"Vellinga","year":"2024","journal-title":"Anesthesiology"},{"key":"R15-20250801","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/ALN.0000000000003102","article-title":"Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: Part II. Pharmacodynamics of electroencephalogram effects","volume":"132","author":"Eisenried","year":"2020","journal-title":"Anesthesiology"},{"key":"R16-20250801","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00540-022-03079-y","article-title":"A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice","volume":"36","author":"Masui","year":"2022","journal-title":"J Anesth"},{"key":"R17-20250801","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/LBR.0000000000000784","article-title":"Correlation of vital signs and depth of sedation by Modified Observer's Assessment of Alertness and Sedation (MOAA\/S) scale in bronchoscopy","volume":"29","author":"Pastis","year":"2022","journal-title":"J Bronchol Interv Pulmonol"},{"key":"R18-20250801","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0952-8180(02)00348-3","article-title":"Relationship between clinical endpoints for induction of anesthesia and bispectral index and effect-site concentration values","volume":"14","author":"Kim","year":"2002","journal-title":"J Clin Anesth"},{"key":"R19-20250801","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2125.1988.tb03346.x","article-title":"Respiratory and cardiovascular effects in relation to plasma levels of midazolam and diazepam","volume":"25","author":"Sunzel","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"R20-20250801","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00000542-198012000-00010","article-title":"Respiratory depression by midazolam and diazepam","volume":"53","author":"Forster","year":"1980","journal-title":"Anesthesiology"},{"key":"R21-20250801","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1213\/00000539-198804000-00016","article-title":"Sedative doses of midazolam depress hypoxic ventilatory responses in humans","volume":"67","author":"Alexander","year":"1988","journal-title":"Anesth Analg"},{"key":"R22-20250801","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/bja\/66.4.454","article-title":"Effect of i.v. midazolam on the ventilatory response to sustained hypoxia in man","volume":"66","author":"Dahan","year":"1991","journal-title":"Br J Anaesth"},{"key":"R23-20250801","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1213\/00000539-198310000-00012","article-title":"Respiratory depressant effects of different doses of midazolam and lack of reversal with naloxone--a double-blind randomized study","volume":"62","author":"Forster","year":"1983","journal-title":"Anesth Analg"},{"key":"R24-20250801","first-page":"1104","article-title":"Effect of intravenous midazolam on breathing pattern and chest wall mechanics in human","volume":"57","author":"Morel","year":"1984","journal-title":"J Appl Physiol Respir Environ Exerc Physiol"}],"container-title":["European Journal of Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/EJA.0000000000002045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T16:00:49Z","timestamp":1754064049000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/EJA.0000000000002045"}},"subtitle":["A randomised controlled trial"],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/eja.0000000000002045","relation":{},"ISSN":["0265-0215","1365-2346"],"issn-type":[{"value":"0265-0215","type":"print"},{"value":"1365-2346","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]}}}